421 related articles for article (PubMed ID: 30144504)
21. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
22. Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.
Armstrong LC; Westlake G; Snow JP; Cawthon B; Armour E; Bowman AB; Ess KC
Hum Mol Genet; 2017 Dec; 26(23):4629-4641. PubMed ID: 28973543
[TBL] [Abstract][Full Text] [Related]
23. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
25. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
26. Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
Zordan P; Cominelli M; Cascino F; Tratta E; Poliani PL; Galli R
J Clin Invest; 2018 Apr; 128(4):1688-1706. PubMed ID: 29389670
[TBL] [Abstract][Full Text] [Related]
27. Neuron-Glia Interactions Increase Neuronal Phenotypes in Tuberous Sclerosis Complex Patient iPSC-Derived Models.
Nadadhur AG; Alsaqati M; Gasparotto L; Cornelissen-Steijger P; van Hugte E; Dooves S; Harwood AJ; Heine VM
Stem Cell Reports; 2019 Jan; 12(1):42-56. PubMed ID: 30581017
[TBL] [Abstract][Full Text] [Related]
28. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
Shah OJ; Wang Z; Hunter T
Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
[TBL] [Abstract][Full Text] [Related]
29. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
30. Modeling tuberous sclerosis complex with human induced pluripotent stem cells.
Niu W; Siciliano B; Wen Z
World J Pediatr; 2024 Mar; 20(3):208-218. PubMed ID: 35759110
[TBL] [Abstract][Full Text] [Related]
31. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
32. A complex interplay between Akt, TSC2 and the two mTOR complexes.
Huang J; Manning BD
Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
[TBL] [Abstract][Full Text] [Related]
33. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
34. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
35. Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
Jurca CM; Kozma K; Petchesi CD; Zaha DC; Magyar I; Munteanu M; Faur L; Jurca A; Bembea D; Severin E; Jurca AD
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833359
[TBL] [Abstract][Full Text] [Related]
36. RHOA signaling defects result in impaired axon guidance in iPSC-derived neurons from patients with tuberous sclerosis complex.
Catlett TS; Onesto MM; McCann AJ; Rempel SK; Glass J; Franz DN; Gómez TM
Nat Commun; 2021 May; 12(1):2589. PubMed ID: 33972524
[TBL] [Abstract][Full Text] [Related]
37. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
Meikle L; Pollizzi K; Egnor A; Kramvis I; Lane H; Sahin M; Kwiatkowski DJ
J Neurosci; 2008 May; 28(21):5422-32. PubMed ID: 18495876
[TBL] [Abstract][Full Text] [Related]
38. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation.
Alsaqati M; Heine VM; Harwood AJ
Mol Autism; 2020 Oct; 11(1):80. PubMed ID: 33076974
[TBL] [Abstract][Full Text] [Related]
40. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
Tee AR; Sampson JR; Pal DK; Bateman JM
Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
